Chapter: Psychiatric Pharmacotherapy in the Oncology Patient

1. Identify when it is appropriate to screen or assess a patient receiving oncology treatment for a mental illness.
2. Assess baseline mental health status and medications before starting chemotherapy to ascertain any concerns that must be incorporated into the treatment plan.
3. Evaluate the potential mental health effects of medications used to treat chemotherapyinduced nausea and vomiting.
4. Distinguish when nonpsychiatric medications are being used to treat mental health disorders and how this use might impact oncology treatment.
5. Evaluate the risk of QTc prolongation of common psychiatric medications, incorporating patient-specific factors, including concurrent chemotherapies.
6. Justify the use of psychiatric medications for additive benefits to an oncology treatment plan. 

Chapter: Oral Anticancer–Induced Toxicities and Drug Interactions

1. Apply evidence-based recommendations for assessing drug–drug interactions and adverse effects from oral anticancer therapy.
2. Evaluate common drug–drug interactions for patients taking oral anticancer therapies.
3. Distinguish between different adverse effects from oral anticancer therapies.
4. Design a treatment plan for management of adverse effects from oral anticancer therapies. 

Chapter: Advanced Non-small Cell Lung Cancer

1. Evaluate oncogenic drivers and how a biomarker may be used in the therapeutic management of advanced non–small cell lung cancer (NSCLC).
2. Evaluate treatments for the management of advanced NSCLC.
3. Design strategies to prevent and mitigate adverse effects and promote adherence in patients receiving oral tyrosine kinase inhibitor therapies for advanced NSCLC. 

Chapter: Metastatic Colorectal Cancer

1. Analyze the appropriate molecular profiling markers for the treatment of a patient with metastatic colorectal cancer (mCRC).
2. Develop a plan for the management of toxicities associated with epidermal growth factor receptor inhibitors.
3. Evaluate the efficacy and safety of regimens used for the treatment of HER2 (human epidermal growth factor receptor 2)-positive mCRC.
4. Assess the role of systemic therapies in the treatment of patients with refractory mCRC.
5. Distinguish the benefits and risks associated with the use of immune checkpoint inhibitors in patients with dMMR/MSI-H (DNA mismatch repair/microsatellite instability high) mCRC. 

Chapter: Sickle Cell Disease

1. Apply evidence-based recommendations in the treatment of sickle cell disease (SCD).
2. Evaluate novel disease-modifying therapies for patients with SCD.
3. Distinguish treatment differences between patients with hemoglobin SC and homozygous hemoglobin SS disease.
4. Analyze curative therapeutic modalities for patients with SCD.
5. Assess health care disparities that exist for patients with SCD. 

Chapter: Hemolytic Anemias

1. Distinguish the differences between the various etiologies of hemolytic anemias and the laboratory parameters used in evaluation and monitoring.
2. Assess the role of newly approved pharmacologic therapies for the treatment of various hemolytic anemias.
3. Evaluate immune-mediated and enzymopathy-related hemolytic anemias and design a treatment plan based on the underlying etiology.
4. Distinguish between the acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome, and design a treatment plan relevant to each microangiopathic hemolytic anemia.
5. Develop a supportive care plan for using complement inhibitors in the management of hemolytic anemias. 

Case Series: Thrombophilia

1. Evaluate individual patients for etiology, risk factors, and laboratory testing relevant in the workup of hereditary and acquired thrombophilia.
2. Design appropriate anticoagulation and management strategies for antiphospholipid syndrome.
3. Distinguish the risk of thrombosis and mitigation strategies associated with myeloproliferative neoplasms and paroxysmal nocturnal hemoglobinuria.
4. Design a plan to optimize exogenous hormone therapy in the setting of thrombophilia concerns. 

Case Series: Pain Management and Palliative Care

1. Justify the use of early palliative care in patients with advanced cancer.
2. Design a pharmacotherapy plan to treat malignant pain, including a plan for breakthrough pain.
3. Design a pharmacotherapy plan to manage opioid-induced constipation.
4. Design a pharmacotherapy plan to manage cancer-associated anorexia.